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THE THERAPEUTIC POTENTIAL OF THE CRISPR-CAS9 SYSTEM FOR 
TREATING DUCHENNE MUSCULAR DYSTROPHY 
DAVID RUBIN 
ABSTRACT 
 
The CRISPR-Cas9 gene editing system gives researchers the ability to manipulate 
and edit DNA with unprecedented ease and precision. It was discovered in bacteria as 
part of their adaptive immune system, but has been reengineered to target any double 
stranded DNA. This burgeoning molecular tool has created great excitement as scientists 
are rapidly adopting it to study fields including human gene therapy, disease modeling, 
agriculture, gene drive in mosquitos, and many others. This paper will explore the 
potential impact of CRISPR-Cas9 in human therapeutics. Specifically, the potential of 
CRISPR-Cas9 to treat Duchenne Muscular Dystrophy will be examined.  In several ways, 
this debilitating degenerative disease is an ideal candidate for gene-editing with CRISPR-
Cas9.  Recent progress in the lab has demonstrated the gene editing system’s ability to 
rescue dystrophin protein levels in vivo.  Although CRISPR-Cas9 holds great promise for 
previously incurable diseases, there are still many limitations that must be overcome 
before the gene editing system can be used in patients. This paper will discuss these 
barriers as well as recent advancements to overcome them.  
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 1 
INTRODUCTION 
  
For decades, the introduction and refinement of new powerful DNA-analyzing 
techniques have continued to profoundly expand our knowledge of the intricacies of the 
genetic code, as well as our ability to harness that knowledge for medical advancement.  
The discovery of the Clustered Regularly Interspersed Short Palindromic Sequence – 
CRISPR Associated Protein 9 (CRISPR-Cas9) gene editing system is the most recent 
addition to the molecular toolbox that gives scientists the ability to manipulate DNA with 
tremendous precision and ease.  
The modified CRISPR-Cas9 gene editing system is a two-component system 
consisting of a bacterial derived nuclease, termed CRISPR-associated protein 9 (Cas9), 
and an engineered RNA strand, termed guide RNA (gRNA). The gRNA guides the 
nuclease to a homologous sequence in the target DNA, and the nuclease cleaves the 
DNA. By simply altering the gRNA sequence, the endonuclease can be redirected to 
target any double stranded DNA sequence of any living organism.  Scientists have used 
the specificity of this gene editing system to study and make advancements in a wide 
range of fields, including human gene therapy, disease modeling, agriculture, gene drive 
in mosquitos, and many others.1 
 
Overview of the CRISPR-Cas9 mechanism 
The CRISPR-Cas9 system naturally occurs in bacteria as part of their adaptive 
acquired immune system to defend against viruses, called bacteriophages.2  Bacterial 
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DNA contains a series of short palindromic repeats, called CRISPR repeats. When 
bacteria become infected with a bacteriophage to which they have never been exposed, 
most cells will die. However, in the event that a bacterium manages to survive the 
infection event, it will cleave the bacteriophage into multiple DNA fragments 
approximately 20-30 nucleotides long and use those fragments to protect itself from 
future infections (Figure 1). The 20-30 nucleotide fragment of the invading 
bacteriophage, termed protospacer, is inserted between the CRISPR repeats in the 
bacterial DNA, at which point the protospacer is termed a spacer. If a subsequent 
infection occurs, the bacteria will transcribe the CRISPR repeat with the spacer into 
mRNA, called CRISPR RNA (crRNA). The mRNA maturates as crRNA fuses with 
another RNA, called transactivating RNA (tracrRNA), to form a crRNA-tracrRNA 
complex.  The crRNA-tracrRNA then associates with and guides a Cas9 protein to the 
invading viral DNA.  The Cas9 protein creates a double break in the viral DNA to disable 
the virus. Over time, a bacterial cell and its progeny will develop a repertoire of viral-
derived spacers that serve as an adaptive immune system.3   
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Figure 1. Bacterial Adaptive Immune System. Phase I, Immunization: During an infection, a bacterial cell 
cleaves the invading viral DNA and inserts the fragments (spacers) between CRISPR repeats. Phase II, 
Immunity: Upon reinfection by the same bacteriophage, the bacterial cell transcribes the CRISPR locus. The 
final products are CRISPR mRNA with the viral spacers, a tracrRNA, and the Cas9 endonuclease  protein. The 
tracrRNA links the CRISPR mRNA with the Cas9 endonuclease (maturation). The CRISPR mRNA guides the 
Cas9 endonuclease to the invading viral DNA by complementary base pairing, and the Cas9 endonuclease 
creates a double strand break to deactivate the virus. Figure taken from (Zhao et al. 2014).4 
 
In addition to a crRNA-tracrRNA, the Cas9 nuclease also requires a protospacer 
adjacent motif (PAM) sequence to be adjacent to the target DNA in order to cut.  PAM 
sequences are located immediately on the 5’ end of the target DNA and are typically 3-5 
nucleotides in length.  There is a wide variety of Cas9 variants found in the prokaryotes, 
and each variant recognizes a specific PAM sequence.  For example, the PAM sequence 
of the most commonly used Cas9 variant, from the strain Streptococcus pyogenes, is –
NGG.  Therefore, the CRISPR-Cas9 will only cleave its target DNA if there is a –NGG 
adjacent to it.  The PAM sequence limits the number of sites in DNA where a Cas9 
nuclease can cleave.  New Cas9 variants are being discovered in bacteria at a rapid pace, 
giving researchers more PAM sequence options for their experiments.  
Originally intended to target invading viral DNA, researchers have manipulated 
the CRISPR-Cas9 system to make edits to mammalian and plant DNA.5,6  In 2012, a 
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landmark study by Jinek et al. first demonstrated that the CRISPR-Cas9 system is 
programmable using a synthetic engineered gRNA, which is substituted for the crRNA-
tracrRNA complex7.  Using a gRNA, Jinek et al. demonstrated that the Cas9 nuclease can 
be guided to any DNA sequence by simply providing a complimentary gRNA.  Quite 
remarkably, CRISPR-Cas9 has shown the ability to edit DNA in nearly any cell: fungi, 
plant or animal cells8,6,5.   Since manufacturing a small gRNA molecule is easy, fast, and 
inexpensive, the two-component system enables researchers to easily modify DNA. 
A promising role for CRISPR-Cas9 is for gene therapy to treat or cure human 
disease. The system offers many advantages over current gene therapy approaches, such 
as antisense oligonucleotides (AON).  However, since the CRISPR-Cas9 technology is 
still in its infancy, there are still many technical hurdles that need to be overcome.  Major 
impediments include the system’s specificity, efficacy, delivery system, and the type of 
DNA repair that occurs after cleavage.  However, significant progress has been made in 
each of these areas within the past few years.1,9 
 
Overview of Duchenne Muscular Dystrophy 
Research for Duchenne Muscular Dystrophy (DMD) has seen encouraging results 
in the lab using the CRISPR-Cas9 system.10–12  DMD is a fatal X-linked disease caused 
by a mutation or deletion in the dystrophin gene that results in a disrupted reading frame 
and a completely non-functional dystrophin protein, frequently a result of a premature 
stop codon.11  The dystrophin protein is a key structural component of dystrophin-
glycoprotein complex that connects the myofiber to the surrounding extracellular matrix.  
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The dystrophin gene is the largest in the human body at 2300 kilobases and encodes for 
79 exons.  Its large size makes it vulnerable to mutations.  Without a functional 
dystrophin protein, a person with DMD will have progressive muscle wasting leading to 
early death, typically due to complications with the lungs and heart.  The average life 
expectancy for a person with DMD receiving proper care is 27.9 years.13 There is 
currently no cure for DMD and the main focus of treatment is managing the symptoms. 
In recent years, DMD researchers have explored using a gene therapy approach 
called exon-skipping to restore the dystrophin protein and recover muscle function.10–12 
This approach skips the mutated exon or exons in order to restore the dystrophin reading 
frame.  The product of exon-skipping is a truncated dystrophin protein that is still 
partially functional and results in Becker Muscular Dystrophy (BMD), a much less severe 
and more manageable form of muscular dystrophy than DMD.14  AONs, which are 
antisense RNAs, have been used to induce exon-skipping during pre-mRNA processing 
and they are currently in clinical trials.11  However, among other pitfalls, AONs require 
repeated administration because the oligonucleotides have a limited half-life. 
The CRISPR-Cas9 system offers a more permanent solution to induce exon-
skipping since it acts directly on the genome and any genetic changes will persist after 
cell replication.  By targeting and cleaving DNA in the flanking introns, CRISPR-Cas9 
excises the mutated exon.  The gene product will be a truncated mRNA with an intact 
reading frame.  This CRISPR-mediated approach to exon skipping on the genetic level 
has been successfully demonstrated in mouse DMD models.10–12  In vivo studies in 
 6 
mouse models showed increased dystrophin protein expression in both skeletal and 
cardiac muscles.10–12  
By targeting multiple exons for excision with CRISPR, rather than a single exon, 
treatments can be targeted for large patient populations.  Exons 45 through 55 are a 
particularly prone to mutations and account for roughly 62% of DMD cases.16  Therefore, 
a treatment that excises these 11 exons could be applied to the majority of DMD cases.  
Interestingly, a truncated dystrophin protein missing exons 45 through 55 is still 
functional and only results in a very mild form of BMD, if the patient isn’t asymptomatic 
altogether.17 
While CRISPR-mediated exon skipping holds great promise for treating DMD, 
there are still many obstacles to solve before this can be used in humans, as mentioned 
above.  A significant challenge for DMD is that treatment will require in vivo 
administration to muscle cells.  Adeno-associated vectors (AAV) have been used to 
deliver CRISPR to DMD models and showed modest efficacy levels.11,12,10  CRISPR 
delivery remains a major hurdle for DMD researchers. 
The unparalleled ease of genetic engineering with CRISPR-Cas9 brings serious 
ethical considerations and concerns.  While somatic cell modifications hold the potential 
to cure many sick individuals, germ line modifications could erase diseases from family 
lineages altogether.  Roughly two-thirds of DMD cases are due to an inherited mutation 
from the mother.18  Removing the dystrophin mutation from the germ cell would prevent 
inheritance of these DMD cases. However, long term consequences of editing human 
germ line cells are unknown.  The ability to modify genes could also lead to so-called 
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“designer babies” whose traits could be chosen by the parents.  The consequences of 
germline editing are so great that an international summit was held in Washington D.C. in 
December 2015 to discuss how scientists should proceed with this technology in an 
ethical manner.  
CRISPR-Cas9 holds great potential for treating human disease and individuals 
with DMD stand to benefit greatly from CRISPR-mediated exon-skipping.  However, 
there are many technical challenges that must be solved before this technology can be 
used in patients. 
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HISTORY OF CRISPR 
  
The discovery and characterization of the bacterial CRISPR system comes from 
an unlikely source: the dairy industry.19  A thorough review of the history of CRISPR is 
beyond the scope of this paper, however, a brief review of its history is important to 
understanding its gene-editing capabilities, and select landmark papers will be discussed 
in this section. 
 Although the biological role of the CRISPR system would not be elucidated for 
many years, Ishino et al. in 1987 were the first to characterize the presence of short 
palindromic repeats located in E. coli downstream from the Iap gene they were 
studying.20  Their paper ended by simply stating “the biological significance of these 
sequences is not known.”20 It would be twenty years until that answer was solved. 
The discovery of these CRISPR arrays went largely ignored until 2005, when two 
labs independently hypothesized that CRISPR functions as a bacterial adaptive immune 
system.21,22  The labs noticed that the DNA located between CRISPR repeats matched 
viral DNA, leading them to hypothesize that bacteria have an adaptive immune system 
against bacteriophages.  
In 2007, scientists at Danisco, a company that sells dairy, were the first to 
successfully demonstrate the CRISPR adaptive immune system in bacteria. The dairy 
industry depends on bacteria cultures to transform milk into cheeses and yogurts. Phage 
infections, which can kill entire bacteria cultures, had always been a significant source of 
food spoilage, ruining roughly 2% of cheese production and up to 10% of yogurt 
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products worldwide and leading to tens of millions of dollars in lost revenue.19  At the 
Danisco labs, Barrangou et al. exposed the Streptococcus thermophiles bacteria, a major 
species used in cheese and yogurt production, to attenuated phages.2  They found that 
exposed bacteria that survived infection had integrated viral spacers into the CRISPR 
arrays, enabling them to survive future infections by the same bacteriophage.  Danisco 
capitalized upon this research by vaccinating its bacterial cultures with over 600 
attenuated phages before ramping up its dairy production.  CRISPRized dairy products 
greatly improved Danisco’s yield and increased the company’ profits.  Today, the 
majority of dairy cultures are vaccinated with attenuated phages to gain CRISPR 
immunity.19 
From 2008 to 2011, after Danisco’s successful demonstration of CRISPR 
adaptive immunity, researchers made progress in understanding the mechanisms behind 
CRISPR.  In 2008, Brouns et al. discovered that viral spacers in the CRISPR arrays are 
transcribed into crRNA, undergo a maturation process, and serve to guide the Cas9 
endonuclease to its target DNA.23  In 2011, Deltcheva et al. further described the crRNA 
maturation process and determined the crRNA forms a duplex with tracrRNA.24 
One of the biggest breakthroughs came in 2012, when Jennifer Doudna’s lab at 
the University of California, Berkeley, demonstrated that CRISPR can be manipulated to 
serve as a programmable gene editing system by replacing the crRNA-tracrRNA complex 
with an engineered gRNA.7  
The following year, Cong et al. and Mali et al. each successfully demonstrated 
CRISPR’s abilities to target eukaryotic DNA, including human DNA.5,25  This discovery 
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transformed the significance of CRISPR from a relatively obscure bacterial curiosity to a 
gene-editing powerhouse that can be applied to any cell.  CRISPR technology has since 
become a ubiquitous tool in gene-editing. 
Since 2013, much of the field’s focus has been on improving CRISPR’s 
specificity, efficacy, and delivery system.  The technology has been used in proof-of-
concept studies to edit genes implicated in familial hypercholesterolemia, cataracts, cystic 
fibrosis, HIV, and Duchenne Muscular Dystrophy.12,26,27  
CRISPR has raised many ethical concerns, especially regarding its ability to 
permanently alter germline cells.  In 2015, Chinese scientists were the first to use 
CRISPR-Cas9 in human embryos.28  Although the embryos used were not viable, the 
study was viewed as irresponsible by many in the scientific field.  The backlash from this 
study helped lead to an International Summit on human gene editing, where scientists met 
in Washington D.C. to discuss how to responsibly proceed using a biological tool with 
unmatched gene-editing potential.29 
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COMPONENTS OF CRISPR-CAS9 
  
An evolutionary arms race between bacteria and phages has yielded many types 
of CRISPR systems to defeat the constantly mutating bacteriophages.30 Currently, 
researchers group the CRISPR systems into three main types. Type I and Type III 
CRISPR systems use gRNA and a nuclease-complex comprised of multiple proteins. 
Type II systems use a gRNA and a single nuclease protein. The simplicity of the Type II 
system makes it the preferred system in the lab. 
This section will discuss the major components of the Type II CRISPR system 
and how they function together.  Many of the current limitations using the CRISPR 
technologies are set by the natural boundaries of the Type II system. Therefore, the 
ability manipulate these components is crucial to using CRISPR for gene-editing.  
 
Cas9 variants  
 Wild-Type Cas9 
 The Wild Type (WT) CRISPR-Cas9 Type II system is a two-component system 
consisting of a gRNA and Cas9 nuclease and makes a double stranded break at its target 
DNA. The biochemical structure of the Cas9 nuclease and gRNA have helped elucidate 
CRISPR’s mechanism of action. This has enabled researchers to manipulate the system to 
create modified CRISPR systems, including Cas9 nickases, catalytically dead Cas9 
(dCas9), and enhanced specificity Cas9s (eSpCas9). 
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 The WT Cas9 is a bi-lobed structure made of an alpha-helical recognition lobe 
and a nuclease lobe and connected by an arginine-rich bridge helix (Figure 2).  The 
recognition lobe contains the Recognition I (REC I) subunit, which is responsible for 
recognizing and loading the gRNA. The nuclease lobe contains the RuvC and HNH 
nuclease domains, the PAM interacting domain, and the Recognition II (REC II) 
domain.31,32  
The RuvC and HNH nuclease domains in the nuclease lobe are conserved across all Cas9 
variants in bacteria. The HNH domain cleaves the DNA strand complementary to the 
gRNA and the RuvC domain cleaves the non-complementary strand. In the wild type 
CRISPR system, these domains usually cleave the same location in the target DNA 
resulting in a blunt double stranded cleavage.  Occasionally, the cleavages will result in 
small one or two nucleotide overhangs. 
 For the Cas9 nuclease become catalytically active, it must associate with the 
gRNA. The REC I subunit binds the gRNA, which initiates a conformational change and 
activates the Cas9 complex. The gRNA, which is an engineered RNA, has two regions 
and is engineered to mimic the endogenous bacterial CRISPR-Tracr RNA. One region is 
the stem-loop scaffold which mimics the tracrRNA.  It is recognized by REC I and 
stabilized onto the Cas9. Upon binding, the Cas9 undergoes a conformational change into 
an active form.  The other region of the gRNA is the complimentary guide sequence, 
which targets a specific sequence in the DNA to be cleaved. 
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Upon binding to a homologous DNA target, another conformational change in the Cas9 
protein initiates the nuclease activity in the RuvC and HNH domains, creating a DSB at 
the target. 
 
Figure 2. Wild Type Cas9 Structure. Figure taken from Cavanagh & Garrity, “CRISPR Mechanism”, 
CRISPR/Cas9, Tufts University, 2014.33 
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 Cas9 nickase mutant 
A drawback of the WT Cas9 is its high rate of off target effects, or low 
specificity.  The gene editing system permits a certain degree of mismatch between the 
gRNA and the target DNA, especially for mismatches that occur close to the PAM 
sequence.  According to Shen et al., up to five gRNA-DNA mismatches can be 
tolerated.34  These mismatches may result in many hundreds of off-target cleavages. 
Creating high specificity Cas9 variants will be critically important in potential future 
applications like gene editing in DMD.  Off-target DNA cleavages could result in 
deleterious and mutagenic effects.  With this in mind, effort has been made to create Cas9 
variants with improved specificity. 
A double-nicking approach using two modified Cas9s, called Cas9 nickases, has 
greatly improved specificity while still maintaining high on-target effects.34,35  By 
inactivating one of the two nuclease domains, a Cas9 protein is only able to nick one of 
the DNA strands at its target (Figure 3). Using two Cas9 nickases, each targeting a 
different DNA strand, a researcher can target two DNA sequences in close proximity.  
Two single stranded breaks (SSB) in opposite DNA strands in close proximity will 
generate a DSB. The probability of off-target cleavages is significantly reduced because 
each of the Cas9 nickases would need to cleave DNA in close proximity to the other. 
When only one Cas9 nickase binds and nicks an off-target site, DNA will repair the nick 
with high fidelity base excision repair. 
The Zhang lab at Harvard created the Cas9 nickases by identifying the precise 
catalytic residue in each nuclease domain responsible for creating the double stranded 
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breaks and introducing point mutations at those residues.35  The lab induced a H840A 
mutation in the HNH nuclease domain and a D10A mutation in the RuvC domain. The 
mutant H840A and the D10A Cas9 nickases cleave the non-complementary strand and 
complementary strand, respectively. 
The double-nicking approach is currently one of the best approaches for 
minimizing off-target effects and has been shown to be effective in vitro and in vivo.  
Careful consideration must be given to choosing target DNA for each nickases.  The 
optimal distance to offset each gRNA seems to be about -10 to +30 base pairs apart, and 
results in robust DNA cleavage.  Due to the offset nickase activity, the final DNA 
cleavage products will have large overhangs. 
 
 Dead Cas9 mutant 
Inactivating both nuclease domains in the WT Cas9 yields a dCas9 (Figure 3b).  
While a dCas9 cannot cleave DNA, it still retains the ability to target and bind to DNA 
sequences that match its gRNA and PAM sequence.  This catalytically inactive Cas9 
variant significantly broadens the potential applications of the CRISPR-Cas9 system. 
Applications using the dCas9 include transcriptional repression with CRISPR 
interference (CRISPRi), transcriptional activation with CRISPR activation (CRISPRa), 
and DNA labeling with GFP.  
CRISPRi is an effective and reversible tool that offers many benefits over RNA 
interference (RNAi), another commonly used method for downregulating gene 
expression.  CRISPRi represses gene expression with much higher efficiency (up to 
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99.9% repression) and no detectable off-target effects.36  It is also able to downregulate 
multiple genes at once (multiplexing) and is effective in both eukaryotes and 
prokaryotes.36  There are two main mechanisms that CRISPRi uses to repress gene 
expression.  One method is to target the promoter region of the gene so the dCas9 
sterically hinders the RNA polymerase. Increasing the number of dCas9s with unique 
gRNAs around a gene’s promoter will create more steric hindrance and increased 
repression of the gene.  The other method is to fuse the repressor domain KRAB to the 
dCas9.37  RNAi has lower efficiency and more toxic effects than CRISPRi.  Additionally, 
RNAi cannot be used in microbes because it relies on eukaryotic machinery to be 
effective.  CRISPR-Cas9 offers significant advantages over the popular RNAi gene 
regulating approach.  Since dCas9 represses gene expression at the DNA level, it gives 
researchers a new tool to combat retroviruses, like HIV.1   
The dCas9 variant does have its limitations.  Like all CRISPR applications, the 
target DNA must have the proper PAM sequence for the dCas9 to have any effect. This 
impediment will become less of a concern as more Cas9 variants with different PAM 
sequences are discovered.  Additionally, the density of the chromatin structure, whether 
heterochromatin or euchromatin, will impact the efficacy of the CRISPRi repression.  
This limiting factor is unique to CRISPRi because it functions at the DNA level.  
 The dCas9 variant can also be used to improve live cell imaging capabilities. By 
tagging the dCas9 to a Green Fluorescent Protein (GFP), researchers can track the target 
DNA throughout the cell cycle.  Since the CRISPR system allows for multiplexing, using 
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multicolored GFPs allows for the simultaneous tracking of many DNA targets.  Ma et al. 
showed this approach can be used to track multiple chromosomes at once.38 
 
Figure 3. Cas9 Variants. B. The Wild Type Cas9 variant has functional HNH and RuvC nuclease domains that 
cleave the complementary and non-complementary strand, respectively. The Cas9 D10A nickase has a mutation 
in the RuvC nuclease and will only cleave the complementary strand. The Cas9 H840A nickase has a mutation 
in the HNH domain, and will only cleave the non-complementary strand. Using the nickases together results on 
a high efficiency system with low off target effects. C. The dCas9 has both nuclease domains inactivated and can 
be used for gene repression. Figure taken from (Doudna and Charpentier, 2014).1 
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 High Specificity Cas9 
 One of the biggest drawbacks using the CRISPR-Cas9 system are its off-target 
effects.  If CRISPR is ever to be used clinically, it is critically important that these 
cleavages are significantly reduced, if not eliminated.  The search for Cas9 variants with 
low off-target effects is taking a two-pronged approach. The first approach is to search 
for naturally occurring high-specificity variants in bacteria. The second approach is to 
modify current Cas9 variants into “High Specificity Cas9” variants.  The latter approach 
requires a deep understanding of the biochemistry of the system so appropriate 
modifications can be made. As our knowledge of the CRISPR-Cas9 system grows, so 
will our ability to manipulate and improve the specificity of the Cas9 nuclease. 
 High specificity Cas9 proteins are constantly evolving.  Researchers have tested 
modifying several components of the CRISPR-Cas9 system.  One approach simply 
decreased the amount of Cas9 in the cell.39  While this decreased off-target activity, it 
also decreased on-target efficacy.  The most effective approach to date aims to reduce the 
affinity between the CRISPR-Cas9 system and the target DNA.39  Two interactions 
contribute to the stabilization of CRISPR-Cas9 and target DNA.  One contributor is the 
degree of homology between the gRNA and the target DNA, and the other is due to 
interactions between the negatively charged DNA backbone and a positively charged 
groove in the Cas9 nuclease.  Replacing positively charged amino acids in the Cas9 
groove with neutral amino acids will decrease the affinity and stabilization between 
CRISPR-Cas9 and the target DNA.  The rationale for this method, led by the Joung and 
Zhang labs at Harvard University, is that the modified CRISPR-Cas9 system will still be 
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able to bind DNA that is perfectly homologous, but off-target locations with mismatches 
to the gRNA will be less likely to bind.40,39 
  
PAM Sequences 
 A necessary component for the CRISPR-Cas9 system is the recognition of the 
PAM sequence on the target DNA by the Cas9 protein. Without this recognition, Cas9 
will not cleave the target DNA even if the gRNA is a perfect match to the target. The 
PAM sequence is a 3-5 nucleotide long sequence that is located on the 5’ end of the 
target DNA. Recognition of the PAM sequence is the first step in the CRISPR’s 
recognition of the target DNA. If the correct PAM sequence is adjacent to the target 
DNA, the Cas9 will open the target DNA and the gRNA will match with its target DNA. 
If both the PAM sequence and gRNA match the target, the Cas9 will proceed to cleave 
the target DNA 3 nucleotides upstream from the PAM sequence. 
 The Cas9’s strict requirement for its PAM sequence is a limiting factor when the 
PAM is not located adjacent to the DNA of interest. Efforts to overcome this hurdle have 
taken two main approaches. One approach is to search the bacterial kingdom for 
undiscovered Cas9 variants that contain different PAM sequence requirements.41(p1)  The 
second approach is to modify existing Cas9 endonucleases to recognize gene specific 
PAMs.  
The first Cas9 endonuclease was discovered in Streptococcus pyogenes (SpCas9), 
which uses a –NGG PAM sequence, and is the most widely used Cas9 variant.35  Since 
then, researchers have discovered hundreds of other naturally-occurring Cas9 variants 
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that recognize many distinct PAM sequences.42   Some of the more frequently used Cas9s 
in gene-editing experiments are listed in Table 1.  Not only do numerous PAM options 
expand the possible targets in the genome, but they permit a varying degree of specificity.  
For example, while the -NGG PAM sequence recognized the SpCas9 is ubiquitous 
throughout the human genome, the -NGRRN/-NGRRT sequence recognized by the S. 
aureus Cas9 (SaCas9) occurs less frequently.  Therefore, the SaCas9 variant and its 
accompanying gRNA may have fewer target sites throughout the genome, resulting in 
fewer off-target DNA effects. 
Table 1. Cas9 variants in the bacterial kingdom recognize a variety of PAM sequences, greatly expanding our 
ability to selectively choose a DNA target. (N=any, R=purine, W=weak bond) Table taken from CRISPR 101: A 
Desktop Resource.43 
   
 
 The Joung Lab at Harvard University has taken a different approach to addressing 
the limits due to PAM sequences by re-engineering the PAM sequence of the SpCas9.44 
By mutagenizing the PAM recognition area on the SpCas9, mutant SpCas9 variants were 
created with artificially chosen PAM recognition sequences. The lab’s two most 
successfully mutated variants, D1135V/R1335Q/T1137R (VQR) and 
D1135E/R1135Q/T1337R (EQR), displayed a robust ability to recognize their PAM 
sequences with equal efficacy as their wild-type counterpart. These new SpCas9 variants 
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enable researchers to target areas of the genome that are not accessible using the wild-
type -NGG sequence. Another variant, D1135E, recognized the same -NGG sequence as 
the wild-type SpCas9 but with greater specificity, leading to fewer off-target effects.  
 As researchers continue to build a library of Cas9 variants with variable PAM 
sequences, either natural or engineered, there will be an increased ability to more 
precisely edit DNA targets while limiting off-target effects.   
 
gRNAs 
All Cas9 variants must associate with a gRNA to be guided to the target DNA.  
The gRNA is an engineered RNA approximately 100 nucleotides that replaces the 
CRISPR-tracr RNA found in endogenous bacterial systems.  First described by Jinek et 
al. in 2012, the RNA molecule must have two functional domains.7  The 5’ end of the 
gRNA is a scaffold region to associate with the Cas9 nuclease.  The scaffold domain of 
the gRNA accounts for roughly 80 of the 100 nucleotides.  The 3’ end of the gRNA is the 
nucleotide guide sequence to guide the Cas9 to the target and accounts for the 20 of the 
100 nucleotides.7    
The length of the gRNA, position of mismatches, number of mismatches, and 
sequence of the gRNA all contribute to the specificity of the gRNA-Cas9 complex. 
gRNAs with longer guide sequences produce more off target effects.  As Fu et al. notes, 
this may seem counterintuitive because longer guide sequences have more nucleotides for 
the target DNA to match.45  However, additional nucleotides will actually stabilize the 
gRNA-DNA interaction which may allow the guide sequence to tolerate some 
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mismatches.  Modification of the guide sequence length has been explored to improve the 
specificity of the Cas9 system.  A truncated guide sequence would remove any mismatch 
tolerance and require near-perfect homology.  Most guide sequences in WT CRISPR 
systems are 20 nucleotides long. Fu et al. demonstrated that using a truncated 17 
nucleotide guide sequence decreased off-target effects by up to 5000x while maintaining 
the same on-target efficacy.45 Guide sequences with fewer than 17 showed little or no 
cleavage activity, so 17 nucleotides appears to be the optimal length.  Using a truncated 
gRNA is a simple way to greatly increase the specificity of the CRISPR-Cas9 system. 
 The guide sequence tolerates certain mismatches better than others.  The first 7-12 
nucleotides of the guide sequence, which will match with the DNA immediately adjacent 
to the PAM site, require a stringent match.46  This region is the 3’ end of the guide 
sequence and is called the seed sequence (see Figure 3 for directionality of gRNA).  Any 
mismatch between the seed sequence and the DNA will prevent CRISPR from binding 
and cleaving.  However, the more distal 5’ end of the guide sequence was can tolerate up 
to two mismatches very well.  Three mismatches significantly decreases CRISPR 
activity, though CRISPR activity in up to five mismatches has been seen.34,47 
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MODES OF DNA REPAIR 
  
After the Cas9 nuclease cleaves its target, the DNA is repaired by either Non-
Homologous End-Joining (NHEJ) or Homology Directed Repair (HDR).  NHEJ is the 
dominating pathway and is cell-cycle independent, while HDR repair occurs less 
frequently and mostly during the S and G2-phase.48 
 
Non-homologous End-Joining 
NHEJ is a crude repair mechanism that ligates the blunt ends of DNA. 
Occasionally, the Cas9 nuclease will not cleave both strands evenly, which creates a 
small base overhang.  If the overhangs on each DNA strand are complementary, they will 
recombine without any mutations. However, small base mutations may occur when the 
DNA is cleaved and they can create a mismatch between the two DNA strand overhangs.  
In this event, the NHEJ repair pathway inserts or deletes a few bases to correct the 
overhang mismatch so it may proceed with blunt-end ligation. The insertion or deletion 
of base pairs creates mutations in the DNA, called indels.49 A single NHEJ event has high 
fidelity and correctly repairs breaks up to 70% without producing an indel.50  However, 
correctly repaired cleavages without indels will still have an intact PAM sequence and 
target DNA, making it vulnerable to another cleavage event. If the subsequent cleavage 
event creates an indel in the PAM sequence or target sequence, the CRISPR-Cas9 cannot 
re-cleave the target and the indel mutation remains. The iterative process of cleaving, 
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repair, and re-cleaving will result in a high likelihood of a mutation at the target site using 
NHEJ.50 
 NHEJ is well suited for gene therapy in diseases caused by a single gene, called 
monogenic diseases.  As the preferred method of DNA repair, researchers do not have to 
make special preparations to shift the cell-cycle to a specific phase or to add additional 
components, as they do with HDR.51–53   The goal when using NHEJ to treat monogenic 
diseases is to shut off a disease-causing segment of DNA.  CRISPR research using NHEJ 
is much more developed and efficient than HDR-mediated gene replacement therapies, 
and will likely be used sooner to treat disease. 
 There are two main approaches to using NHEJ therapeutically.  One method is the 
loss-of-function approach, which uses CRISPR-Cas9 to introduce indels at the disease-
causing gene.  The indels could be introduced at either a regulatory element upstream of 
the gene, or in the actual gene itself.  For example, researchers at Harvard University 
have provided a proof of concept study showing that inducing loss-of-function mutations 
in the PCSK9 gene in mice significantly reduces blood LDL levels and decreases the 
likelihood of cardiovascular disease.54  When targeting a gene using NHEJ, the target 
DNA should be towards the beginning of the gene sequence, which will increase the 
likelihood of an early nonstop codon and a nonfunctional protein.  This loss-of-function 
approach can also be used in the lab to make knock-out disease models quickly and 
cheaply. 
 In addition to inducing loss-of-function mutations, NHEJ can also be used to 
induce gene deletion.  By designing a pair of Cas9s to flank and cut a target gene, or 
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portion of a gene, one can simply delete a segment of DNA.  DMD is a model disease for 
this method since its mutation can usually be isolated to a single exon in the dystrophin 
gene.  The gRNAs are designed to target the introns adjacent to the target exon.  Indels 
induced in these regions are not problematic since the DNA will not be expressed into 
gene products.  The simultaneous cleavage on each side of the implicated exon will 
remove it from the DNA.  The resulting product is a truncated but still partially functional 
dystrophin protein.  
 
Homology Directed Repair  
HDR uses a homologous repair template to copy and paste a novel DNA sequence 
into the site of the DSB (Figure 4). The repair DNA template, which must be co-
delivered to the cell with the CRISPR components, contains a desired DNA insert flanked 
by DNA regions that are homologous to the target strand.  When Cas9 cleaves the DNA, 
the target DNA invades the repair template and copies its sequence. The result is a 
modified target strand with a novel gene sequence. HDR is less error-prone than NHEJ, 
since the donor template is homologous to the target strand, so it is less likely to induce 
mutations. 
 Modifying and inserting desired genes with HDR could be used to treat many 
more diseases than is possible with NHEJ.  Diseases with specific point mutations are 
particularly good targets using HDR.  The template DNA required for diseases caused by 
point mutations is small, which improves the efficacy of HDR-mediated repair.  For 
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example, Huang et al. were able to correct the sickle cell point mutations in bone marrow 
derived pluripotent stem cells.55 
However, even with small DNA templates, the knock-in efficiency of HDR is less 
than 10%.43  A major current area of study is to determine how to shift the balance from 
NHEJ repair to HDR repair, which would enable researchers to target and treat many 
more diseases. 
 
Figure 4. Homology-Directed Repair. Figure taken from Cavanagh & Garrity, “CRISPR Mechanism”, 
CRISPR/Cas9, Tufts University, 2014.33 
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DUCHENNE MUSCULAR DYSTROPHY 
 
DMD is in an ideal candidate for CRISPR-mediated gene therapy.  It can take 
advantage of the NHEJ pathway to excise mutated exons, producing a truncated but 
functional dystrophin protein. Rescue of the dystrophin protein results in a BMD 
phenotype, which has a much better prognosis than a DMD phenotype.  Significant 
progress has been made in recent years using CRISPR to treat DMD both in vitro and in 
vivo, and it appears that DMD may be one of the first diseases to use CRISPR clinically.  
This section will describe the role of the dystrophin protein, the progression of DMD, and 
how CRISPR may be used to treat or cure the disease. 
 
The Dystrophin-Glycoprotein Complex 
 The Dystrophin-Glycoprotein Complex (DGC) is an essential structural 
component of muscle (Figure 5).  It connects and transmits force between the 
intracellular F-actin cytoskeleton and the extracellular basal lamina.56  Dystrophin plays a 
key role as part of the DCG.  The protein’s N-terminal domain binds to the myofibers F-
actin cytoskeleton and the cysteine-rich C-terminal domain anchors itself to the 
sarcolemma-bound -dystroglycan subunit.  The center of the dystrophin protein is a long 
central-rod domain made of numerous spectrin-like repeats.  When dystrophin is mutated 
or missing, the F-actin cytoskeleton and the sarcolemma do not move as a single unit.  
The sarcolemma loses integrity and becomes permeable, leading to necrosis of the 
myofiber.57  
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The severity of muscular dystrophies is quite variable and depends on the type 
and location of a mutation.  Mutations in the N- or C-terminal domain will likely cause 
severe Duchenne- like phenotypes because the dystrophin protein cannot anchor itself to 
the F-actin or the B-dystroglycan, respectively.57  Nonsense mutations in the central-rod 
domain will also result in Duchenne phenotypes because there is no functional protein 
produced.  However, mutations in the repetitive central-rod domain are candidates for 
exon skipping therapies, which would create a shorter but functional central-rod domain. 
Approximately 80% of DMD mutations are in the central-rod domain and can 
theoretically be treated with exon skipping.15  Mutations in the N- or C-terminal domain 
will not benefit from exon skipping, as each exon in these regions are uniquely important 
and necessary. 
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Figure 5. The Dystrophin-glycoprotein Complex. Figure taken from Ameen and Robson, 2010.58 
 
Progression of DMD 
Care for DMD and BMD patients requires a multidisciplinary team to treat the 
slow and predictable decline in muscle function. Current treatment has a two-pronged 
approach.  First, physicians hope to slow the progression of the disease.  As muscle cells 
die and function declines, the main goal is to reduce inflammation and maintain cardiac 
and pulmonary function. While there is still no cure, improvements in detection and early 
treatment with glucocorticoids have extended the average life expectancy from 17.7 years 
to 27.9 years.13  These improvements have pushed back the ages at which symptoms first 
appear throughout a patient’s life.  Since the majority of patients diagnosed with DMD 
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receive the current standard of care, the updated natural history of DMD in a patient 
receiving this current standard is discussed below.  
Though the severity and timing of the disease and symptoms varies case-by-case, 
DMD follows a fairly predictable four-stage course: early ambulatory, late ambulatory, 
early non-ambulatory, late non-ambulatory.59 
 The early ambulatory stage occurs roughly from ages 2 through 7.60  DMD is 
usually diagnosed towards the beginning of this stage as the child misses normal 
developmental milestones.  It is sometimes detected before these physical manifestations 
through increased serum creatine kinase or increased transaminases as a result of muscle 
breakdown.59  If suspected, a genetic test must be performed to confirm the diagnosis.  
During the early ambulatory stage, symptoms are mainly restricted to problems with 
motor function.  Leg muscles are the first to deteriorate.  Although the child is able to 
walk, he will be slow to stand up and will quickly become fatigued.  To stand, the child 
will use his hands to push off the ground and then his thighs, a maneuver called Gowers 
sign (Figure 6).  Gowers sign is one of the earliest diagnostic indicators that helps parents 
and physicians to suspect DMD.  Other physical symptoms during this stage include a 
waddling gait, toe walking, and difficulty climbing stairs.  Calf-muscles will be enlarged 
due to muscle fibrosis, called pseudohypertrophy.  The fibrosis will decrease flexibility of 
muscles and joints, further impeding the child’s ability to walk. Cardiac and pulmonary 
function during this phase are not yet affected. 
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Figure 6. Gowers S ign. Figure taken from Wikipedia.61  
 
 The late ambulatory stage occurs from ages 7 to 9.  In many ways, this stage is 
simply a more advanced version of the early ambulatory stage. Physical exertion 
becomes increasingly harder and more taxing. Stairs are very difficult by this point. The 
patient will walk on his toes and push his belly forward as he walks, to compensate for 
poor balance due to weakened leg and core muscles.  Also by this age, patients become 
increasingly cognizant of their differences from their peers, and are twice as likely to 
develop emotional or behavioral problems as the average child.62  A patient will still have 
full use of his upper arms through this stage. 
 By the early non-ambulatory age, typically from ages 10-14, patients are 
restricted to wheelchairs. Additionally, cardiac and lung function begin to decline during 
this stage. The patients will develop dilated cardiomyopathy, which is a thickened but 
weakened ventricular wall due fibrosis.63  Congestive heart failure develops as the heart 
muscle continues to weaken and the ejection fraction declines.  A weakened diaphragm 
decreases ventilation and the ability to cough, putting the patient at high risk for lower 
respiratory infections.64  The declining cardiac and pulmonary function are monitored 
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very closely since they are the two most common causes leading to death in DMD.  The 
patient’s core muscles will continue to atrophy, leading to early signs of scoliosis in 95% 
of patients after loss of ambulation.65  Upper arm weakness will also begin to develop. 
 The late non-ambulatory stage begins around age 15.  This stage is characterized 
by life-threatening declines in vital functions and loss of control of the arms.  Respiratory 
insufficiency will progress to the point where a patient will require a 24-hour Bilevel 
Positive Airway Pressure (BiPAP) machine initially through either a mouthpiece but later 
on through a tracheostomy.64  Maintaining a proper weight is very difficult during this 
stage. Many patients are underweight because they cannot reach their hands to their 
mouths to feed themselves. Additionally, loss of control of the pharyngeal muscles will 
increase aspiration and regurgitation events.  Conversely, many patients struggle with 
obesity due to glucocorticoid treatment which increases appetite. Death will most likely 
occur from sudden respiratory and cardiac failure, which account for 35% and 40% of 
deaths related to DMD, respectively.66 
 
Current Treatments 
 There are very few treatments that manage to delay the progression of the DMD.  
The two most prominent treatments include glucocorticoids and gene therapy AONs.   
Currently, glucocorticoids are the only FDA approved treatment for DMD and are 
used universally.  They reduce inflammation that occurs with muscle degeneration. 
Additionally, they increase muscle strength and delay loss of ambulation by about two 
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years.67  Increased muscle strength significantly delays the decline in cardiac and 
pulmonary function, and also delays the onset of scoliosis.  Schram et al. found the 15-
year survival rate increases by 50% in patients on glucocorticoid treatment, allowing 
patients to reach their mid-to-late twenties68  Patients are typically started on 
glucocorticoid treatment in the early ambulatory stage during the “plateau phase”, when 
their motor abilities seem to have peaked.69 
Unfortunately, chronic glucocorticoid treatment comes with many side effects 
which limits its use. Some of the more severe side effects include: weight gain, 
Cushingoid appearance, glucose intolerance, osteoporosis, hypertension, and cataracts.67  
Management of these side effects must be monitored very closely and dosages should be 
modified accordingly. 
AONs are a potential future therapy for DMD that may prevent the onset of 
symptoms and even partially reverse the disease.  DMD is an ideal candidate for exon-
skipping gene therapy with AONs because an individual’s mutation can be localized to a 
specific exon.  AONs are oligonucleotides that have complementary sequences to their 
target pre-mRNA.  They prevent the spliceosome complex from binding and splicing 
splice site on both sides of the target exon during pre-mRNA processing by steric 
hindrance.70  As a result, the target exon is included in the excised portion of DNA when 
a spliceosome cuts the next splice site in the downstream mRNA.  The processed mRNA 
will have skipped the mutated exon, which restores the reading frame of the dystrophin 
protein. 
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AONs may represent a promising future in DMD gene therapy, but the 
technology has its pitfalls.  The drug is a biologic, and therefore very difficult and 
expensive to produce.  It would need to be administered in hour-long weekly sessions for 
the entirety of the individual’s life due to a limited half-life.71  The requirement for 
repeated administrations also adds to the cost.  Lastly, AONs poorly penetrate cardiac 
muscle, which is problematic since cardiac failure is a big contributor to DMD deaths.10  
There are currently no FDA-approved AONs, but AONs targeting several exons 
are being developed.15  Recently, two of the more promising drugs under development 
and targeting exon 51, eteplirsen and drisapersen, were each rejected in early 2016 for 
underpowered and poorly controlled studies.  Clinical studies for rare diseases like DMD 
are particularly difficult due to challenges in recruiting viable candidates.  Not only are 
there a very small number of people with DMD in the United States (about 9,000 - 
12,000), but there is a huge variation in genotypic mutations causing DMD.  For 
example, exon 51 is the most commonly mutated exon causing DMD, but represents only 
13% of DMD patients.72  Sarepta, the developer of eteplirsen, used just 12 patients in its 
study phase III clinical trial without concurrent controls.70  For controls, they used 
historical DMD patient data, which the FDA found insufficient. 
The current pharmacologic options to delay the progress of DMD are very 
limited.  Glucocorticoids have helped to slow the progression of the disease, but have 
very serious side effects. Gene therapy with AONs may become a capable treatment, but 
their current efficacies remain in question. 
 35 
DMD EXON SKIPPING 
  
 DMD is an ideal candidate for CRISPR-mediated exon skipping.  Although 
clinically-ready treatment is still far from being available, research has progressed at a 
rapid pace in recent years to demonstrate the viability of CRISPR-mediated exon 
skipping in cultured human muscle cells as well as in in vivo animal models.   
 An advantage of CRISPR-mediated exon skipping over AON-mediated exon 
skipping is CRISPR’s “one-size-fits-all” approach.  DMD is a heterogeneous disease; the 
location of mutation varies person-to-person and can occur anywhere in the 2300 
kilobase dystrophin gene.  This poses a challenge for AONs, which can only target one 
exon at a time to be skipped during the pre-mRNA processing.  Eteplirsen and 
drisapersen can only excise exon 51 because they are only homologous to the splice-site 
regions in the adjacent introns.15  An exon 51 mutation is the most common mutation, yet 
applies to just 13% of DMD patients.  To account for the other DMD patients, 
pharmaceutical companies would need to engineer an AON for each individual exon.  
The enormous drug approval costs and the innate challenges of running clinical trials for 
a rare disease makes this approach unfeasible.  Even by targeting the most commonly 
mutated exon, Sarepta Pharmaceuticals was unable to find enough participants to create a 
well-controlled study for eteplirsen.  Targeting rarer DMD mutations would exacerbate 
the problem.  Cocktail AON mixtures have been explored to individually skip multiple 
exons, but have been plagued by limited efficacy and concern over mixed-length 
dystrophin intermediates.17,71  
 36 
The regenerative capacity of muscle stem cells, called satellite cells, also gives 
CRISPR an advantage over AONs.10  As satellite cells divide, it dilutes the concentration 
of AONs in each cell.  Meanwhile, a permanent genetic deletion induced by CRISPR will 
propagate down the entire satellite cell’s lineage. 
CRISPR’s multiplexing ability gives it yet another significant edge over AON.  
By using just two gRNA-guided Cas9 nucleases, the CRISPR system can excise multiple 
exons together (Figure 7).  Some regions in the dystrophin gene are particularly active 
mutational hotspots.  Excision of these hotspots could account for a majority of DMD 
cases.  The most active spot for dystrophin mutations is from exon 45 through exon 55, 
which account for 62% of all DMD cases.73  This region has been successfully targeted 
and excised as one DNA fragment in multiple in vitro experiments in human myocytes.  
The first successful experiment used twelve gRNAs to target all twelve introns in the 
hotspot region.73  More recently, Young et al. and Ousterout et al. demonstrated that 
using just two gRNAs targeting the introns before exon 45 and after exon 55 was 
sufficient to excise the entire 336 kb hotspot.73,74  Unlike cocktail AONs, a two-gRNA 
guided CRISPR approach will have an all-or-nothing effect, without unknown impact of 
dystrophin intermediates.   
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Figure 7. Multi-Exon Skipping Strategies. Figure taken from Ousterout et al.73 
 
A look at BMD patients with naturally occurring 45-55 exon deletions may help 
shed light on the functional ability of a CRISPR-induced 45-55 exon deletion.  It appears 
that a truncated dystrophin protein of this type maintains most of its function.  In a 
retrospective study, Taglia et al. found that BMD patients with a 45-55 deletion have 
particularly mild symptoms, if they are not asymptomatic altogether.16  The patients live 
nearly normal lives with minimal muscle atrophy and no effect on respiratory function.  
Cardiac function may be very slightly impaired.  The majority of these BMD cases were 
discovered from elevated creatine kinase levels in routine lab tests, with one patient not 
diagnosed until age 62.  The study does not have data on life expectancies but their 
prognosis is clearly substantially better than DMD patients.  While these BMD patients 
give promise to a potential CRISPR-mediated exon 45-55 deletion, there are still several 
reasons to be cautious.  Like many muscular dystrophy studies, the patient sample size 
was very small (n=9).  Additionally, the current understanding and role of dystrophin is 
incomplete, and a CRISPR-mediated 45-55 deletion may not be equivalent to a 45-55 
deletion in BMD patients.  Future studies should clarify the functionality of dystrophin 
with a CRISPR-mediated 45-55 deletion.  
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 Although still many years away, an interesting question going forward for a 
clinical CRISPR “one-size-fits-all” approach is whether or not the FDA would allow a 
single treatment to cover many DMD genotypes.  In this case, each individual receiving 
the 45-55 CRISPR deletion would have one mutated exon and ten fully functional exons 
removed.  Given the good prognosis of BMD patients with a 45-55 deletion, this may 
seem like a reasonable approach.  Alternatively, the FDA could require eleven separate 
treatments for mutations the 45-55 region with each treatment only removing the mutated 
exon.  This approach is more patient-specific and eliminates the superfluous deletion of 
ten functional exons.  More information is needed on the functional capabilities of 
various truncated dystrophin proteins. 
 
CRISPR In Vivo 
In vitro studies in human myoblast cells have demonstrated CRISPR’s ability to 
modify the dystrophin gene, but these proof-of-concept studies using the CRISPR system 
must be utilized in vivo to be used clinically.  DMD researchers, perhaps more than 
researchers in any other field, are pushing the frontier of CRISPR technology to optimize 
it for in vivo use.  Three landmark papers from the Olson, Wagers, and Gersbach labs 
demonstrating in vivo administration of CRISPR to treat DMD were published 
simultaneously in Science on January 22, 2016.11,12,10  Each lab rescued dystrophin 
protein expression in animal models enough to show an improved muscle function, as 
well as restored expression in the heart and diaphragm. 
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DMD as a Candidate for CRISPR Gene Editing 
DMD is one of the first diseases to explore using CRISPR for gene editing.  The 
disease is well-suited to use current CRISPR technology because it only requires NHEJ 
in post-mitotic muscle cells, which has already been achieved in vitro.  Additionally, 
muscle function improves and survival is prolonged with as little as 5% dystrophin 
expression in humans.75  DMD researchers also have good animal models, called mdx 
mice, to test various components of the system.   
A benefit of the NHEJ pathway is that it is cell-cycle independent, and therefore it 
can edit both pre- and post-mitotic cells. Conversely, HDR is cell-cycle dependent, less 
efficient, and requires the co-delivery of a DNA template. Conveniently, the targets of 
DMD treatment are post-mitotic muscle fibers which can take advantage of the more 
efficient NHEJ pathway. 
The DMD animal model used for in vivo studies are mdx mice which have a 
nonsense mutation in exon 23.76  There are valid concerns about whether mdx mice are 
suitable models.  The model has a much weaker muscular dystrophy phenotype than 
DMD patients.  The most notable difference is that mdx mice rarely develop 
cardiomyopathy.  The models do, however, develop diaphragm and distal limb muscle 
degeneration.  While the mdx model is not perfect correlate to DMD in terms of clinical 
manifestations, its mutated exon provides a good target to test the viability of CRISPR in 
vivo.  For the purpose of CRISPR studies, this is sufficient. 
Technical components of the in vivo CRISPR system still need to be optimized 
for DMD.  One of the current limitations is the delivery method, which uses an AAV 
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capsid to deliver the gRNA and Cas9 nuclease to the target tissue.  Additionally, the 
treatment must be capable of editing all muscles, but especially the heart and diaphragm, 
whose degeneration is a common cause of death in DMD patients.  To be used clinically, 
off-target effects must be minimized.  Progress has been made in each of these areas to 
show that in vivo CRISPR-mediated gene editing for DMD is viable. 
Use of AAV vectors has enabled DMD researchers to achieve modest success in 
delivering CRISPR to its target cells in vivo.  In nature, adenoviruses package their DNA 
into an icosahedral capsid to be delivered animal host cells.  Removing the viral genes 
and replacing them with a vector containing the sequence for a Cas9 nuclease and gRNA 
will allow delivery of CRISPR to cells.  AAVs are particularly well suited for DMD 
because of their ability to transduce postmitotic cells, which include muscle fibers.  
As of 2014, there are 13 naturally occurring AAV serotypes, each of which vary 
in their preference for targeting specific cell types.77   Serotypes AAV8 and AAV9 are 
best suited to treat DMD because they are both highly cardiotropic and have good 
transduction rates when administered systemically.77  Given that heart failure is accounts 
for 40% of DMD deaths, it is important that a gene therapy can effect cardiac muscle.66  
AAV9 may be more preferable than AAV8 because it appears to be more tropic for 
skeletal muscle.  Two of the three landmark papers published in January 2016 used 
AAV9 (Olson and Wagers lab), while the other used AAV8 (Gersbach lab).11,12,10  The 
serotypes were both effective rescuing dystrophin in cardiac tissue, but AAV9 rescued 
more skeletal muscle.  Additionally, use of AAV8 resulted in successful dystrophin 
expression in the diaphragm and abdomen muscles, but not in the distal limbs.  Under the 
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same conditions, use of the AAV9 serotype resulted in dystrophin expression in all 
skeletal muscle, including the distal limbs.  While these studies were able to deliver 
enough gRNA and Cas9 to target cells in mice with a relatively small amount of AAVs, 
humans would require many more AAVs due to the larger size, which may be 
problematic in a clinical setting.   
Immunogenicity to AAVs is very low.  Humans frequently have natural 
antibodies against some serotypes, most commonly AAV1, 2, 3, and 5.78  However, 
natural antibodies against AAV8 and AAV9 are uncommon, reaffirming the subtypes as 
good candidates for DMD gene therapy. 
  AAV capsids have a cargo limit of ~4.5 kb in length, which eliminates many 
Cas9 variants from consideration for in vivo delivery.  The most commonly used Cas9 
variant for in vitro studies, SpCas9, is below the limit at 4.2 kb.  The Olson lab 
successfully used SpCas9 packaged in AAVs in its in vivo study.12  However, since 
SpCas9 is just barely under the limit, it leaves little room for additional components like 
multiple gRNAs, which is needed for exon excision.  A smaller Cas9 would help alleviate 
this size limit problem.  Ran et al. screened 600 naturally occurring Cas9 variants from 
different bacteria to find a smaller yet equally efficient and specific Cas9 variant.42  The 
SaCas9, at just 3.2 kb, fit the search criteria.  The variant’s long PAM sequence (-
NGRRN) may also help reduce potential off-target sites. The Wagers and Gersbach labs 
successfully rescued dystrophin expression using the SaCas9 (Figure 8).11,10   
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Figure 8. Restored dystrophin expression in cardiac muscle using a dual vector system with SaCas9.  Left – 
Immunofluorescence Staining shows dystrophin in WT mice.  Center – Dystrophin is absent in untreated mdx 
mice.  Right – Dystrophin levels are partially recovered in mdx mice treated with a dual vector system 
containing SaCas9.  Figure taken from Nelson et al.11 
 
 A dual-vector delivery system is another way to overcome the capsid’s packaging 
limits.  A dual-vector system packages the Cas9 variant in one vector, and two gRNAs 
that flank the mutated exon 23 are packaged in the other vector (Figure 9).  Upon 
cotransfection of a cell, the gRNAs will associate with the Cas9s to cleave the flanking 
introns of exon 23.  This dual-vector approach reduces the cargo size in each vector.  
Comparison of the ability to excise exon 23 with single versus dual-guided system using 
SaCas9 in mdx myotubes showed the dual-guided system to be more robust.10  As smaller 
Cas9 variants are discovered, it may be possible to fit all the components into one vector 
which could improve efficacy. 
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Figure 9.  Dual-Vector Delivery System.  Using a Dual-Vector delivery system, one AAV expression cassette 
contains the Cas9 variant (top) and the other AAV expression cassette contains multiple gRNAs (bottom). 
Figure taken from CRISPR 101: A Desktop Resource (1st edition).43 
 
 
 Selection of a good gRNA is critical for better efficacy and for limiting off-target 
effects.  A gRNA with the fewest matches in the genome is the least likely to cleave off-
target sites.  Currently, selection of a gRNA must be done manually.  In DMD studies 
using mdx mice, researchers manually search intron 22 and 23 for PAM sites close to the 
exon.  The 20-30 nucleotide sequences located the 5’ end of the PAM sites are potential 
candidate sequences for the gRNAs. A genome-wide assessment of the gRNA candidates 
is then done to determine which has the fewest matches.  Zhang lab at Harvard University 
has created an algorithm to rank the most likely off-target locations for a given gRNA 
sequence.79 
 In the three in-vivo DMD studies from January 2016, virtually no off-target 
effects were detected from the ten most likely off-target candidates.  This finding greatly 
alleviated concern that CRISPR could not be specific enough to be used therapeutically.  
Still, off-target effects may occur at other sites.  As the technology progresses towards 
clinical use, genome-wide detection of DSBs must be done.  The Joung lab at Harvard 
University has developed GUIDE-Seq, a method created with CRISPR in mind that 
performs an unbiased genome-wide search for DSBs.80  Looking forward, studies may 
 44 
want to explore using advances in high specificity Cas9 variants like esCas9 or use a 
double nicking approach to limit off-target effects. 
 
 
Recent Progress in Rescuing Dystrophin Expression 
 The three simultaneously published articles in Science on January 22, 2016, made 
significant progress towards the possibility of using CRISPR-mediated gene editing in 
DMD patients.10–12  They are the first to demonstrate that the approach is feasible and 
provide a foundation for future in vivo CRISPR studies.  The results from these studies 
will be discussed in this section. 
 The Gersbach lab partially recovered dystrophin expression in mdx mice through 
intramuscular (IM), intraperitoneal (IP), and intravascular (IV) routes of administration.11  
IM has its gene-editing effects locally, while IP and IV reach systemic circulation more 
quickly and have body-wide effects.  CRISPR delivered IM to the tibialis anterior muscle 
showed improved twitch and tetanic strength after 8 weeks.  Biochemical analysis 
revealed that just 2% of the alleles in these muscle fibers were successfully edited.  While 
this low level of editing is disappointing, it rescued dystrophin protein levels to 8% of 
WT levels.  Recall that as little as 5% can produce phenotypically noticeable differences.  
While 8% is a good starting point, the goal moving forward should be to reach at least 
29-57% efficacy, which is the range where humans become asymptomatic for DMD.14  
Another finding from this paper showed 57% of the total dystrophin mRNA transcripts 
were the corrected versions without exon 23.  Nelson notes this large percentage is 
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probably because the transcripts with the nonsense mutation in exon 23 quickly undergo 
nonsense mediated decay.  In total, 67% of myofibers showed some increase in 
dystrophin protein expression.  The lab also saw improved histology when compared to 
untreated mdx muscle fibers.  In particular, there was substantially reduced inflammation 
and reduced white blood cell infiltration.  In a clinical setting, this would reduce the need 
for glucocorticoid treatment. 
 The Gersbach lab also did IP and IV CRISPR injections in neonatal and 
adolescent mice to determine the effects of systemic-wide circulation of CRISPR.  The 
progressive and irreversible nature of muscle degeneration in DMD makes it important to 
rescue dystrophin levels at an early age.  Both routes of administration showed increased 
dystrophin levels in cardiac muscle and skeletal muscle in the diaphragm and abdomen 
(Figure 8).  Data of cardiac and pulmonary function over the lifetime of the mice were 
not included in the study, though this may be of interest for future studies.  A better 
understanding of the relationship between tissue-specific dystrophin rescue and improved 
function is needed.  Lastly, the lab showed that rescued dystrophin levels remain present 
at 6 months after treatment.  This is particularly encouraging because it suggests that very 
few or perhaps only one treatment of CRISPR is sufficient.  This would make CRISPR 
treatment significantly more affordable and convenient than weekly AON treatments.  
 The Wagers lab also successfully restored dystrophin expression in mdx mice by 
IM and IP routes.10  The lab found that on average 39% of mRNA transcripts from IM 
administration were missing exon 23.  Systemic circulation by IP injection showed more 
variable results, ranging from 3% to 18%.  Wagers did not quantify the percentage of 
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dystrophin protein that was recovered compared to WT, but histology with 
immunofluorescence revealed an increase in dystrophin protein.  Mice injected both IM 
and IP showed increased strength in distal limbs.  Additionally, other critically important 
tissues showed increased dystrophin protein levels including the heart, diaphragm and 
abdomen. 
 A significant finding from the Wagers lab was that muscle stem cells, called 
satellite cells, can be edited with CRISPR.10  Therefore, damaged muscle fibers can be 
replaced with functional substitutes.  CRISPR editing does not appear the hamper the 
regenerative capacity of satellite cells. Two weeks after both IP and IM delivery of 
CRISPR, satellite cells were harvested, grown in vitro, and successfully differentiated 
into myotubes.  Unfortunately, the amount of mRNA transcripts in the myotubes missing 
exon 23 were quite variable.  Nonetheless, this proof-of-concept shows that satellite cell 
editing is feasible.  This would improve muscle’s ability to heal itself after damage. 
 The Olson lab’s paper far outpaced the other two studies in total amount of 
dystrophin protein recovered.12 The lab successfully rescued dystrophin expression via 
three routes of administration: IM, IP, and retroorbital (RO).  RO is an intravenous route.  
Nelson et al. recorded up to 53.2% dystrophin expression compared to WT in the skeletal 
muscle of the tibialis anterior, and up to 71.1% expression in cardiomyocytes (Figure 10). 
If the system were to remain equally effective in humans, it would well exceed 29% 
threshold where patients start becoming asymptomatic.14  
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Figure 10.  Restored dystrophin expression in cardiac and skeletal muscle using a dual vector system with 
SpCas9.  Semi-quantitative immunohistochemistry used to measure relative density of dystrophin compared to 
WT mice. Left – Dystrophin expression in the tibialis anterior.  Right – Dystrophin expression in cardiac muscle. 
Figure taken from Long et al.12  
   
 Interestingly, although these mdx mice showed significantly improved muscle 
function in strength tests, they did not perform as well as WT mice.  In humans, 
dystrophin levels this high compared to WT result are nearly asymptomatic.  This serves 
as a reminder that although mdx mice provide good genetic targets gene therapy, the mice 
do not have the same clinical manifestations as humans.  
 Several unique findings from the Gersbach lab may have beneficial clinical 
effects.11  In particular, the efficacy of the CRISPR system increases with time.  This is 
likely due to the ability of CRISPR to continuously recognize and cleave a target site 
until an indel is introduced at the PAM location.  As an example, the number of edited 
myofibers from the tibialis anterior increased nearly 18% over a 6-week span after IM 
injection of CRISPR.11  This suggests that in a clinical setting the efficacy of the 
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treatment would improve with time, whereas the efficacy of AON treatment decreases 
with time.  Nelson et al. also showed that as dystrophin protein is rescued, blood serum 
creatine kinase levels decrease.  This helps confirm that muscle degeneration is 
decreasing. 
 The paper also had two unique observations regarding germline cells.  The first 
finding showed that systemic administration of CRISPR did not cause detectible DSBs, 
on or off-target, in germline cells.  The second finding showed that mdx germline cells 
could be edited in vitro and implanted to produce normal offspring.  Of the 27 pups born 
from the edited zygotes, 16 had partial exon 23 deletion.  Furthermore, no off-target 
effects were detected.   
The germline experiment garnered relatively little attention when the three papers 
were co-published, but it raises an important question – is germline editing ethical?  
Although the ability to prevent a deadly disease such as DMD may not be controversial, 
the technology could be harnessed to modify human phenotypes in other ways.  Another 
ethical concern is the lack of informed consent.  Since germline modifications will 
propagate from generation to generation, it is impossible to gain consent from the future 
individuals who will be affected by the treatment and its side effects.  Scientists held an 
international summit in Washington D.C. in December 2015 to discuss these ethical 
issues.  There was a general consensus that implantation of gene-edited embryos should 
not be attempted until more information about safety is available.29  
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Discussion 
  
 CRISPR technology is a burgeoning field and DMD stands to be one of the first 
diseases to benefit from it.  As a monogenic disease that can take advantage of the more 
prominent NHEJ mode of repair, DMD can already use the CRISPR system despite its 
current limitations to show modest increases in dystrophin expression.  The technology, 
whose gene editing potential has only been realized in the past four years, represents a 
bright light in the future of a disease with an otherwise poor prognosis.  This section 
provides novel discussion regarding the current and future state of CRISPR-mediated 
DMD research and boundaries it faces to reach the clinic. 
 There is no disagreement that the current treatment of DMD is insufficient.  It can 
only manage the symptoms but not reverse the debilitating effects. While improvements 
in care including respiratory ventilation and glucocorticoid treatment have increased the 
average life expectancy by 10 years, they come with many side effects that decrease 
quality of life.13  Ultimately, the disease is 100% fatal.   
If exon-skipping gene therapies become available in a clinical setting for DMD, 
they could potentially be the first FDA approved treatment to reverse the progression of 
the disease.  AONs have come tantalizingly close to the clinic in recent months, but the 
most promising drug in clinical trials, eteplirsen, was rejected by the FDA on April 26, 
2016.72  Although CRISPR is certainly far from any clinical trial, in theory it has several 
advantages over AON gene therapy.  AON treatments will have high costs, frequent 
dosing, a very limited ability to target cardiac muscle, and can only target one exon per 
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oligonucleotide.  As discussed throughout this paper, CRISPR successfully addresses 
each of those concerns.  Based on the speed of development of the CRISPR system and 
the current efficacy seen in animal models, it seems likely that CRISPR will eventually 
become the gene editing system of choice to treat DMD clinically. 
 Although CRISPR holds great promise for gene therapy, DMD researchers still 
face challenges including off-target effects and efficacy.  To overcome these obstacles, it 
would be beneficial for future DMD studies to integrate the rapidly advancing CRISPR 
discoveries into their methods.   
In vivo studies encouragingly showed very minimal off-target effects, but there 
must be more certainty that they will not occur if CRISPR is to be used to treat DMD 
clinically.  Advances in improving Cas9 specificity may address these issues.  Using the 
esCas9, a double nicking approach, or a truncated gRNA could significantly limit off-
target effects in DMD experiments.35,40,45  The three in vivo studies from the Long, 
Olson, and Wagers lab each used WT Cas9 variants with 20 nucleotide guide 
seqeunces.11,12,10  If, for example, a future study uses a truncated 17 nucleotide guide 
sequence, off-target effects may decrease by up to 5000 fold.45  Off-target effects will be 
a focal point of CRISPR-mediated gene editing in a clinical setting. 
In addition to limiting off-target effects, DMD researchers can use recent CRISPR 
advances to improve efficacy of dystrophin rescue.  The packing limit of AAVs forces 
current studies to employ a dual vector approach, with one vector containing the Cas9 
and the other containing the gRNAs.  Using a single vector system containing both the 
Cas9 and gRNAs would improve the likelihood that an individual cell receives both 
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CRISPR components.  The rapid discovery of smaller Cas9 variants will enable DMD 
researchers to package more CRISPR components into a single vector.  The discovery of 
SaCas9, which is 1 kb shorter than the original SpCas9, is small enough to use in a 
single-vector delivery system but has not yet been attempted in a DMD study.  As 
knowledge of CRISPR improves, improved control over efficacy and off-target effects 
will bring the gene-editing system closer to the clinic. 
The eteplirsen clinical trials demonstrated that a better understanding of the 
pathogenesis of DMD will be needed to establish a therapeutic benefit of any gene-
therapy drug.  Over one thousand DMD genotypes have been identified, each with the 
potential to have a unique phenotype.  This enormous variability will make it challenging 
to perform clinical trials for any single exon-skipping treatment.  For this reason, a multi-
exonic deletion of the 45-55 region may prove to be beneficial because it can treat 62% 
of patients.11  Another barrier moving forward is the lack of a well-established clinical or 
surrogate endpoint that has been accepted by the FDA.  Although it is logical that 
increased dystrophin levels would improve muscle function, the FDA is not yet satisfied 
with the correlation studies.72  A better understanding of the DMD pathogenesis will help 
establish endpoints to streamline DMD clinical trials and accelerate drug approvals for 
gene-editing therapies. 
CRISPR is a new technology, yet has already demonstrated a remarkable ability 
to edit the genome at precise locations.  New discoveries are being made at a rapid pace.  
This bodes well for the future of DMD treatment, which is poised to be among the first 
diseases to benefit from a CRISPR therapeutic intervention.  While further 
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characterization of both the CRISPR-Cas9 system and DMD pathogenesis is needed, 
families affected by this devastating disease can be hopeful that a life-saving treatment 
may be somewhere on the horizon.  
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